Trial Outcomes & Findings for Treating Pain in Children With Cancer: Pain Buddy (NCT NCT03384134)

NCT ID: NCT03384134

Last Updated: 2026-07-24

Results Overview

As part of the daily electronic Pain Buddy diary, children were administered the Memorial Symptoms Assessment Scale. Children 8-9 years of age received an 8-item instrument and were asked to report frequency (i.e. a very short time, a medium amount, almost all the time) severity (i.e. a little, a medium amount, very), and how distressful (i.e. not at all, a little, a medium amount, very) each symptom was. Children 10-18 years of age received a 30-item instrument and were asked to report how often (i.e. almost never, sometimes, a lot, almost always), how severe (i.e. slight, moderate, severe, very severe), and how distressful (i.e. not at all, a little bit, somewhat, quite a bit, very much) each symptom was. The items related to pain severity were used to calculate a 0-10 continuous score of self-reported pain severity for participants in each group. For this outcome, lower scores represent improvement in pain severity.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

407 participants

Primary outcome timeframe

Baseline and day 60

Results posted on

2026-07-24

Participant Flow

Children and caregivers were recruited in oncology outpatient clinics and inpatient floors at both hospitals (CHOC Children's and St Jude Children's Research Hospital) between August 1, 2019 and May 2, 2024. The Pain Buddy app was designed for child use, thus, only the child was randomized to an arm. These numbers reflect the revised protocol included in this record. The originally reported phases (1, 2, and RCADS sample) have been removed, thus no data is available for reporting.

Caregivers only completed outcome assessments. Although the protocol references additional samples, this group was never recruited separately. All children randomized to either arm of the study completed the RCADS measure.

Participant milestones

Participant milestones
Measure
Parents of Children Randomized to Pain Buddy
Parents of children enrolled in the study were asked to complete surveys but did not use the Pain Buddy application.
Parents of Children Randomized to the Control Group
Parents of children enrolled in the study completed surveys but did not use the Pain Buddy application.
Pain Buddy
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
Control
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
Overall Study
STARTED
110
93
111
93
Overall Study
COMPLETED
75
85
75
85
Overall Study
NOT COMPLETED
35
8
36
8

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Parent sex is unknown/not collected from parents

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Pain Buddy
n=111 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
Control
n=93 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
Parents of Children Randomized to Pain Buddy
n=110 Participants
Parents of children enrolled in the study completed surveys but did not use the Pain Buddy application.
Parents of Children Randomized to Control
n=92 Participants
Parents of children enrolled in the study completed surveys but did not use the mobile health application.
Total
n=406 Participants
Total of all reporting groups
Age, Continuous
12.73 years
STANDARD_DEVIATION 2.99 • n=111 Participants
11.74 years
STANDARD_DEVIATION 2.64 • n=93 Participants
41.06 years
STANDARD_DEVIATION 7.57 • n=110 Participants
40.59 years
STANDARD_DEVIATION 7.8 • n=92 Participants
26.51 years
STANDARD_DEVIATION 15.41 • n=406 Participants
Sex: Female, Male
Female
42 Participants
n=111 Participants • Parent sex is unknown/not collected from parents
47 Participants
n=93 Participants • Parent sex is unknown/not collected from parents
89 Participants
n=204 Participants • Parent sex is unknown/not collected from parents
Sex: Female, Male
Male
69 Participants
n=111 Participants • Parent sex is unknown/not collected from parents
46 Participants
n=93 Participants • Parent sex is unknown/not collected from parents
115 Participants
n=204 Participants • Parent sex is unknown/not collected from parents
Ethnicity (NIH/OMB)
Hispanic or Latino
31 Participants
n=111 Participants
23 Participants
n=93 Participants
27 Participants
n=110 Participants
23 Participants
n=92 Participants
104 Participants
n=406 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
80 Participants
n=111 Participants
70 Participants
n=93 Participants
83 Participants
n=110 Participants
69 Participants
n=92 Participants
302 Participants
n=406 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=111 Participants
0 Participants
n=93 Participants
0 Participants
n=110 Participants
0 Participants
n=92 Participants
0 Participants
n=406 Participants
Race (NIH/OMB)
American Indian or Alaska Native
3 Participants
n=111 Participants
1 Participants
n=93 Participants
4 Participants
n=110 Participants
1 Participants
n=92 Participants
9 Participants
n=406 Participants
Race (NIH/OMB)
Asian
20 Participants
n=111 Participants
17 Participants
n=93 Participants
25 Participants
n=110 Participants
17 Participants
n=92 Participants
79 Participants
n=406 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=111 Participants
0 Participants
n=93 Participants
0 Participants
n=110 Participants
0 Participants
n=92 Participants
0 Participants
n=406 Participants
Race (NIH/OMB)
Black or African American
11 Participants
n=111 Participants
9 Participants
n=93 Participants
9 Participants
n=110 Participants
9 Participants
n=92 Participants
38 Participants
n=406 Participants
Race (NIH/OMB)
White
77 Participants
n=111 Participants
66 Participants
n=93 Participants
72 Participants
n=110 Participants
65 Participants
n=92 Participants
280 Participants
n=406 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=111 Participants
0 Participants
n=93 Participants
0 Participants
n=110 Participants
0 Participants
n=92 Participants
0 Participants
n=406 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=111 Participants
0 Participants
n=93 Participants
0 Participants
n=110 Participants
0 Participants
n=92 Participants
0 Participants
n=406 Participants
Region of Enrollment
United States
111 participants
n=111 Participants
93 participants
n=93 Participants
110 participants
n=110 Participants
92 participants
n=92 Participants
204 participants
n=406 Participants
Visual Analog Scale
61.13 units on a scale
STANDARD_DEVIATION 22.24 • n=111 Participants • The visual analog scale is a continuous measure of patient self-reported pain severity. Thus, parent VAS was not collected.
64.18 units on a scale
STANDARD_DEVIATION 22.48 • n=93 Participants • The visual analog scale is a continuous measure of patient self-reported pain severity. Thus, parent VAS was not collected.
62.52 units on a scale
STANDARD_DEVIATION 22.35 • n=204 Participants • The visual analog scale is a continuous measure of patient self-reported pain severity. Thus, parent VAS was not collected.

PRIMARY outcome

Timeframe: Baseline and day 60

Population: Phase one and phase two participants were not part of the current IRB number (181088) and the "RCADS sample group" was not recruited as a separate arm under this protocol. All children randomized to Pain Buddy or control completed the RCADS measure.

As part of the daily electronic Pain Buddy diary, children were administered the Memorial Symptoms Assessment Scale. Children 8-9 years of age received an 8-item instrument and were asked to report frequency (i.e. a very short time, a medium amount, almost all the time) severity (i.e. a little, a medium amount, very), and how distressful (i.e. not at all, a little, a medium amount, very) each symptom was. Children 10-18 years of age received a 30-item instrument and were asked to report how often (i.e. almost never, sometimes, a lot, almost always), how severe (i.e. slight, moderate, severe, very severe), and how distressful (i.e. not at all, a little bit, somewhat, quite a bit, very much) each symptom was. The items related to pain severity were used to calculate a 0-10 continuous score of self-reported pain severity for participants in each group. For this outcome, lower scores represent improvement in pain severity.

Outcome measures

Outcome measures
Measure
Pain Buddy
n=111 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
Control
n=93 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
Changes in Pain Severity Over Time
6.5 scores on a scale
Standard Error 0.585
4.08 scores on a scale
Standard Error 0.585

SECONDARY outcome

Timeframe: Baseline (T1)

Population: Phase one and phase two participants were not part of the current IRB number (181088) and the "RCADS sample group" was not recruited as a separate arm under this protocol. All children randomized to Pain Buddy or control completed the RCADS measure.

Medication Attitude Questionnaire (MAQ) (parent self-report). This questionnaire was developed to examine attitudes about using pain medication for treating children's pain. The instrument consists of 16 items each rated on a seven-point Likert-type scale that ranges from strongly disagree to strongly agree. The factors were Appropriate-Use, Side-Effects (e.g., "Side effects are something to worry about when giving children pain medication"), and Avoidance (e.g., "Pain medication works best if saved for when the pain is quite bad"). Scores for the side effects scale range from 5-35. Scores for Avoidance range from 7-49. Scores for Appropriate Use range from 4-28 A total score reflective of misconceptions is calculated by summing all the subscales. The total score ranges from 16-112 with higher scores indicating more negative attitudes towards use of pain medication.

Outcome measures

Outcome measures
Measure
Pain Buddy
n=109 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
Control
n=92 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
Medication Attitude Questionnaire (MAQ) (Parent Self-report)
23.37 score on a scale
Standard Deviation 5.11
23.81 score on a scale
Standard Deviation 4.90

SECONDARY outcome

Timeframe: Baseline (T1), day 60 (T2), and day 180 (T3)

Population: The number analyzed in one or more rows differs from the overall number analyzed due to attrition rates across time points, and missing data within measures that did not allow for calculation of scales. Additionally, phase one and two participants were not part of the current IRB number (181088) and the "RCADS sample group" was not recruited as a separate arm under this protocol. All children randomized to Pain Buddy or control completed the RCADS measure as part of the standard survey battery.

Perceived Stress Scale (PSS) (parent self-report) The PSS is a widely used 14-item self-report measure of perceived stress. Parents will be asked to rate statements such as "In the past month, how often have you been upset because of something that happened unexpectedly?" and "In the past month how often have you felt that things were going your way?" Subjects rate the items on a 5-point Likert-type scale. Seven items are reverse-keyed and items are summed to obtain the final score. Total scores range from 0-56. Higher scores reflect greater perceived stress. The PSS has been shown to have adequate reliability and validity. Completed at baseline, 60 days, and 6 month follow-up using REDCap

Outcome measures

Outcome measures
Measure
Pain Buddy
n=109 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
Control
n=92 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
Changes in Perceived Stress (Parent Self-report)
Parent T1- PSS total score
24.01 score on a scale
Standard Deviation 9.06
26.13 score on a scale
Standard Deviation 7.86
Changes in Perceived Stress (Parent Self-report)
Parent T3- PSS total score
21.60 score on a scale
Standard Deviation 9.07
22.05 score on a scale
Standard Deviation 10.13
Changes in Perceived Stress (Parent Self-report)
Parent T2- PSS total score
21.58 score on a scale
Standard Deviation 8.35
23.59 score on a scale
Standard Deviation 8.63

SECONDARY outcome

Timeframe: Baseline (T1)

Population: Parent report of trait inventory. Phase one and two participants were not part of the current IRB number (181088) and the "RCADS sample group" was not recruited as a separate arm under this protocol. All children randomized to Pain Buddy or control completed the RCADS measure as part of the standard survey battery.

State-Trait Anxiety Inventory (STAI) (parent self-report). This is a widely used self-report anxiety assessment instrument for adults.The questionnaire contains two separate, 20-item, 4-point self-report rating scales for measuring trait and state anxiety. TOTAL scores are summed for situational and trait anxiety. Scores range from 20 to 80 each; higher scores denote higher levels of anxiety. For our purposes, only the one page Trait section of the questionnaire will be administered and utilized. Completed at baseline (T1) using REDCap. Scores from 20-37 indicate low anxiety, 38-44 indicate moderate anxiety, and 45-80 indicate high anxiety.

Outcome measures

Outcome measures
Measure
Pain Buddy
n=95 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
Control
n=81 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
State-Trait Anxiety Inventory (STAI) (Parent Self-report)
39.65 score on a scale
Standard Deviation 9.33
41.28 score on a scale
Standard Deviation 8.63

SECONDARY outcome

Timeframe: Baseline (T1) , day 60 (T2) , and day 180 (T3)

Population: The number analyzed in one or more rows differs from the overall number analyzed due to attrition rates across time points, and missing data within measures that did not allow for calculation of total scores. Phase one and two participants were not part of the current IRB number (181088) and the "RCADS sample group" was not recruited as a separate arm under this protocol. All children randomized to Pain Buddy or control completed the RCADS measure as part of the standard survey battery.

The Revised Child Anxiety and Depression Scale (RCADS) -Child's self report on 47-item scale with subscales including separation anxiety, social phobia, generalized anxiety, panic disorder, obsessive compulsive disorder, and major depression. Items are rated on a 4-point Likert scale from 0 ("never") to 3 ("always"). Higher scores suggest higher levels of anxiety and depression. TOTAL Scores range from 0-141.

Outcome measures

Outcome measures
Measure
Pain Buddy
n=110 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
Control
n=92 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
Changes in Children's Anxiety and Depression Assessed Using the Revised Child Anxiety and Depression Scale (RCADS)
Child T1- RCADS total score
27.52 score on a scale
Standard Deviation 15.55
29.18 score on a scale
Standard Deviation 13.29
Changes in Children's Anxiety and Depression Assessed Using the Revised Child Anxiety and Depression Scale (RCADS)
Child T2- RCADS total score
22.28 score on a scale
Standard Deviation 18.30
26.13 score on a scale
Standard Deviation 15.44
Changes in Children's Anxiety and Depression Assessed Using the Revised Child Anxiety and Depression Scale (RCADS)
Child T3 - RCADS total score
22.39 score on a scale
Standard Deviation 18.35
23.62 score on a scale
Standard Deviation 16.09

SECONDARY outcome

Timeframe: Baseline (T1) , day 60 (T2) , and day 180 (T3)

Population: The number analyzed in one or more rows differs from the overall number analyzed due to attrition rates across time points, and missing data within measures that did not allow for calculation of scales. Additionally, phase one and two participants were not part of the current IRB number (181088) and the "RCADS sample group" was not recruited as a separate arm under this protocol. All children randomized to Pain Buddy or control completed the RCADS measure as part of the standard survey battery.

Children and parents are asked to report on the child's health related quality of life. The measure incorporates a generic (divided into 4 categories: physical, emotional, social and school), cancer (divided into 8 categories: pain \& hurt, nausea, procedural anxiety, treatment anxiety, cognitive problems, perceived physical appearance and communication), and fatigue module (divided into 3 categories: general fatigue, sleep/rest fatigue, cognitive fatigue). Higher scores on the scale suggest a better health related quality of life. Questions are asked on a 5-point likert scale ranging from 0=never to 4=almost always. Scores are transformed from 0-100. TOTAL scores for each module range from 0-100 on the PedsQL.

Outcome measures

Outcome measures
Measure
Pain Buddy
n=111 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
Control
n=92 Participants
Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Parent PedsQL Fatigue T1
64.17 score on a scale
Standard Deviation 18.02
65.16 score on a scale
Standard Deviation 17.89
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Parent T1- PedsQL Cancer
66.62 score on a scale
Standard Deviation 16.08
65.51 score on a scale
Standard Deviation 16.16
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Parent T1- PedsQL General
62.58 score on a scale
Standard Deviation 17.98
61.22 score on a scale
Standard Deviation 16.65
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Child T1- PedsQL Fatigue
66.92 score on a scale
Standard Deviation 18.15
65.17 score on a scale
Standard Deviation 19.01
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Child T1- PedsQL Cancer
70.57 score on a scale
Standard Deviation 15.51
70.69 score on a scale
Standard Deviation 15.77
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Child T1- PedsQL General
69.75 score on a scale
Standard Deviation 16.40
68.83 score on a scale
Standard Deviation 16.06
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Parent T2- PedsQL Fatigue
66.87 score on a scale
Standard Deviation 20.67
67.49 score on a scale
Standard Deviation 29.91
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Parent T2- PedsQL Cancer
68.43 score on a scale
Standard Deviation 18.72
66.79 score on a scale
Standard Deviation 15.44
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Parent T2- PedsQL General
64.36 score on a scale
Standard Deviation 19.82
63.80 score on a scale
Standard Deviation 17.43
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Child T2- PedsQL Fatigue
72.41 score on a scale
Standard Deviation 21.82
70.37 score on a scale
Standard Deviation 19.46
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Child T2- PedsQL General
73.12 score on a scale
Standard Deviation 17.23
72.01 score on a scale
Standard Deviation 16.94
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Parent T3- PedsQL Fatigue
71.05 score on a scale
Standard Deviation 21.09
70.07 score on a scale
Standard Deviation 20.92
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Parent T3- PedsQL Cancer
69.83 score on a scale
Standard Deviation 18.55
66.18 score on a scale
Standard Deviation 19.36
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Parent T3- PedsQL General
68.30 score on a scale
Standard Deviation 19.93
66.18 score on a scale
Standard Deviation 19.36
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Child T3- PedsQL Fatigue
75.33 score on a scale
Standard Deviation 19.85
71.12 score on a scale
Standard Deviation 21.28
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Child T3- PedsQL Cancer
77.57 score on a scale
Standard Deviation 17.59
76.41 score on a scale
Standard Deviation 15.15
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Child T3- PedsQL General
75.74 score on a scale
Standard Deviation 17.43
73.71 score on a scale
Standard Deviation 17.48
Changes in Children's Quality of Life Since Using Pain Buddy is Assessed Using the Pediatric Quality of Life Inventory (Child Self-report, Ages 8-12, 13-18; Parent Report Child Ages 8-12, 13-18)
Child T2- PedsQL Cancer
75.91 score on a scale
Standard Deviation 17.09
72.92 score on a scale
Standard Deviation 15.01

Adverse Events

Pain Buddy

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Michelle Fortier

University of California, Irvine

Phone: 714-456-2833

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place